EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies

Megan Reidy, Meerah Khan, Elizabeth A Mills, Qi Wu, Josh Garton iD, Dean E Draayer, Insha Zahoor iD, Shailendra Giri iD, Robert C Axtell iD, Yang Mao-Draayer

International Journal of Molecular Sciences · 19.04.2025 · 26 (8) · 3880

DOI: 10.3390/ijms26083880 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.04.2025. Verfasst von Megan Reidy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Autoimmunity Center of Excellence, Multiple Sclerosis Center of Excellence, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Rese…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Sclerosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIAID NIH HHS, NIH NIAID Autoimmune Center of Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system. The therapeutic landscape for MS has evolved significantly since the 1990s, with the development of more than 20 different disease-modifying therapies (DMTs). These therapies effectively manage relapses and inflammation, but most have failed to meaningfully prevent disease progression. While classically understood as a T cell-mediated condition, the most effective DMTs in slowing progression also target B cells. Novel classes of MS therapies in development, including anti-CD40L monoclonal antibodies, CD19 chimeric antigen receptor (CAR) T cells, and Bruton’s tyrosine kinase (BTK) inhibitors show greater capacity to target and eliminate B cells in the brain/CNS, as well as impacting T-cell and innate immune compartments. These approaches may help tackle the disease at its immunopathological core, addressing both peripheral and central immune responses that drive MS progression. Another emerging therapeutic strategy is to use bispecific antibodies, which have the potential for dual-targeting various disease aspects such as immune activation and neurodegeneration. As such, the next generation of MS therapies may be the first to reduce both inflammatory demyelination and disease progression in a clinically meaningful way. Their ability to target specific immune cell populations while minimizing broad immune suppression could also lead to better safety profiles. Here, we explore the biological rationale, advantages, limitations, and clinical progress of these emerging immunotherapies for relapsing–remitting and progressive forms of MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple SclerosisHumansAnimalsB-LymphocytesT-LymphocytesImmunotherapy

Stichwörter der Autor:innen

BTKiCAR T cellCD19CD20CD40LDMTmultiple sclerosis

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Autoimmunity Center of Excellence, Multiple Sclerosis Center of Excellence, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
  • Alzheimer's Drug Discovery Foundation, 57 West 57th Street, Suite 904, New York, NY 10019, USA.
  • Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Neurology, Henry Ford Health, Detroit, MI 48202, USA.

ORCID-Profile: Josh Garton, Insha Zahoor, Shailendra Giri, Robert C Axtell

Förderung

  • NCATS NIH HHS
  • NIAID NIH HHS
  • NIH NIAID Autoimmune Center of Excellence

Zitieren

APA

Reidy, M., Khan, M., Mills, E. A., Wu, Q., Garton, J., Draayer, D. E., Zahoor, I., Giri, S., Axtell, R. C., & Mao-Draayer, Y. (2025). New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies. International Journal of Molecular Sciences, 26(8), 3880. https://doi.org/10.3390/ijms26083880

Vancouver

Reidy M, Khan M, Mills EA, Wu Q, Garton J, Draayer DE, et al. New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies. International Journal of Molecular Sciences. 2025;26(8):3880. doi:10.3390/ijms26083880

BibTeX
@article{Reidy2025,
  author = {Reidy, Megan and Khan, Meerah and Mills, Elizabeth A and Wu, Qi and Garton, Josh and Draayer, Dean E and Zahoor, Insha and Giri, Shailendra and Axtell, Robert C and Mao-Draayer, Yang},
  title = {New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {8},
  pages = {3880},
  doi = {10.3390/ijms26083880}
}
Kostenlos starten →